Referred to the House Committee on Energy and Commerce.
The bill would bar the FDA from approving new abortion drugs or granting investigational exemptions for drugs used to intentionally terminate pregnancies, rescind certain ongoing investigational exemptions after three years, and impose strict restrictions and a required REMS for previously approved abortion drugs. Restrictions include no labeling changes to expand use beyond 70 days gestation, in-person administration by the prescribing health care practitioner only (no pharmacy dispensing), mandatory practitioner certification and capabilities, extensive adverse-event and administration reporting, and broader practitioner reporting requirements.
Progressives emphasize access losses; conservatives emphasize protecting unborn life.
Relative to its intended legislative type, this bill is a clearly targeted substantive statutory change that is detailed in its prohibitions, definitions, and many operational requirements, but it lacks fiscal provisions and certain implementation and enforcement particulars.
The bill would bar the FDA from approving new abortion drugs or granting investigational exemptions for drugs used to intentionally terminate pregnancies, rescind certain ongoing investigational exemptions after three years, and impose strict restrictions and a required REMS for previously approved abortion drugs.
Restrictions include no labeling changes to expand use beyond 70 days gestation, in-person administration by the prescribing health care practitioner only (no pharmacy dispensing), mandatory practitioner certification and capabilities, extensive adverse-event and administration reporting, and broader practitioner reporting requirements.
The bill defines key terms such as "abortion drug," "adverse event," "gestation," "health care practitioner," and "unborn child."
Highly controversial topic, significant regulatory intrusion, and major Senate procedural and likely legal obstacles make enactment unlikely based on content alone.
Relative to its intended legislative type, this bill is a clearly targeted substantive statutory change that is detailed in its prohibitions, definitions, and many operational requirements, but it lacks fiscal provisions and certain implementation and enforcement particulars.
Progressives emphasize access losses; conservatives emphasize protecting unborn life.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize access losses; conservatives emphasize protecting unborn life.
Likely to view this bill as a severe restriction on medication abortion access and reproductive autonomy.
They would see the provisions as rolling back telemedicine and pharmacy access, adding burdens that disproportionately affect rural and low-income patients.
Views the bill as attempting to enhance patient safety but recognizes significant tradeoffs in access and implementation.
Would weigh safety gains against administrative burdens, costs, and potential unintended consequences.
Likely to view the bill positively as protecting unborn life and preventing expansion of medication abortion access via telemedicine or pharmacies.
Appreciates prohibitions on new abortion drugs and tightened oversight.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Highly controversial topic, significant regulatory intrusion, and major Senate procedural and likely legal obstacles make enactment unlikely based on content alone.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize access losses; conservatives emphasize protecting unborn life.
Highly controversial topic, significant regulatory intrusion, and major Senate procedural and likely legal obstacles make enactment unlikel…
Relative to its intended legislative type, this bill is a clearly targeted substantive statutory change that is detailed in its prohibitions, definitions, and many operational requirements, but it lacks fiscal provision…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.